Contributions
Abstract: PB2209
Type: Publication Only
Background
Aims
Determine the effectiveness of laboratory tests to monitor patients treated with direct oral anticoagulants
Methods
We conducted a retrospective study with 227 patients who received direct oral anticoagulants (DOACs) between January 2015 and December 2016. One hundred eighteen patients (52%) receive Rivaroxaban, fifty patients (22%) receive Dabigatran and fifty nine patients receive Apixaban (26%). We analyzed the variables that’s increases the bleeding risk such as age, weight, prothrombin time (PT) and activated partial thromboplastin time (aPTT), therapeutic range of the drug, and measurement of serum creatinine.
Results
Variable | Apixaban | Rivaroxaban | Dabigatrán |
percentage | 25.9% | 51.9% | 22% |
toxicity | 3.3% | 6.7% | 10% |
thrombotic episodes | 1.6% | 2.5% | 6% |
percentage out of therapeutic range | 8.4% | 24.5% | 22% |
prolonged aPTT | 8.4% | 2.5% | 80% |
prolonged PT | 16.9% | 21% | 4% |
Bleeding | (35) 15.4% | ||
percentage | 34.2% | 20.8% | 7.8% |
prolonged aPTT | 8.3% | 22.2% | 100% |
prolonged PT | 25% | 33.3% | 80% |
median therapeutic range | 177 | 142 | 154 |
median serum creatinine | 1mg/dl | ||
median age | 81 | ||
median weight | 71 |
We found 10% of toxicity with Dabigatran, a 7% with Rivaroxaban and a 3% with Apixaban. Thirty-five patients (15%) developed bleeding of which 11% patients had a minor bleeding and a 4% of patients had a mayor bleeding, we also found that 6% of patients with Dabigatran, 2.5% with Rixaroxaban and 1.5% with Apixaban developed thrombotic episodes. Twenty percent of patient didn’t have therapeutic range of the drug. For each DOACs is shown in Table 1.
Conclusion
In our series, in patients with dabigatran and who suffered bleeding, we found a significant prolongation of aTTP and PT, demonstrating the importance of laboratory tests prior to the administration of these agents and in emergency situations, for these reason should be include PT and aPTT, therapeutic level of the drug and creatinine measurement, within the emergency and control laboratory tests in patients that receive DOACs.
Session topic: 34. Thrombosis and vascular biology
Abstract: PB2209
Type: Publication Only
Background
Aims
Determine the effectiveness of laboratory tests to monitor patients treated with direct oral anticoagulants
Methods
We conducted a retrospective study with 227 patients who received direct oral anticoagulants (DOACs) between January 2015 and December 2016. One hundred eighteen patients (52%) receive Rivaroxaban, fifty patients (22%) receive Dabigatran and fifty nine patients receive Apixaban (26%). We analyzed the variables that’s increases the bleeding risk such as age, weight, prothrombin time (PT) and activated partial thromboplastin time (aPTT), therapeutic range of the drug, and measurement of serum creatinine.
Results
Variable | Apixaban | Rivaroxaban | Dabigatrán |
percentage | 25.9% | 51.9% | 22% |
toxicity | 3.3% | 6.7% | 10% |
thrombotic episodes | 1.6% | 2.5% | 6% |
percentage out of therapeutic range | 8.4% | 24.5% | 22% |
prolonged aPTT | 8.4% | 2.5% | 80% |
prolonged PT | 16.9% | 21% | 4% |
Bleeding | (35) 15.4% | ||
percentage | 34.2% | 20.8% | 7.8% |
prolonged aPTT | 8.3% | 22.2% | 100% |
prolonged PT | 25% | 33.3% | 80% |
median therapeutic range | 177 | 142 | 154 |
median serum creatinine | 1mg/dl | ||
median age | 81 | ||
median weight | 71 |
We found 10% of toxicity with Dabigatran, a 7% with Rivaroxaban and a 3% with Apixaban. Thirty-five patients (15%) developed bleeding of which 11% patients had a minor bleeding and a 4% of patients had a mayor bleeding, we also found that 6% of patients with Dabigatran, 2.5% with Rixaroxaban and 1.5% with Apixaban developed thrombotic episodes. Twenty percent of patient didn’t have therapeutic range of the drug. For each DOACs is shown in Table 1.
Conclusion
In our series, in patients with dabigatran and who suffered bleeding, we found a significant prolongation of aTTP and PT, demonstrating the importance of laboratory tests prior to the administration of these agents and in emergency situations, for these reason should be include PT and aPTT, therapeutic level of the drug and creatinine measurement, within the emergency and control laboratory tests in patients that receive DOACs.
Session topic: 34. Thrombosis and vascular biology